Pre-market hot trades in US stocks: Cava up 7.47% in pre-market; Enigmatig down 7.13% in pre-market

Pre-market Hot Trades in US Stocks

Cava pre-market up 7.47%. Based on recent key news:

1. On May 19, Cava announced its first-quarter financial report, with revenue growth of 32.2% to $434.4 million, exceeding market expectations. Adjusted earnings per share were $0.20, higher than the analyst expectation of $0.17, driving the stock price up. Source: MT Newswires

2. On May 19, Cava raised its same-store sales growth forecast for fiscal year 2026 to 4.5% to 6.5%, and increased its adjusted EBITDA forecast to $181 to $191 million, indicating strong business growth momentum. Source: Reuters

3. On May 19, analysts generally maintained a buy rating, raising the target price to $105, reflecting market confidence in Cava's future performance. Source: Stifel Nicolaus The overall performance of the restaurant industry is weak and requires attention.

Enigmatig, pre-market down 7.13%, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

Top Gainers in Pre-market US Stocks

Micware pre-market up 145.55%. No significant news recently; trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. no_news

GCL Global pre-market up 113.64%. Based on recent key news:

1. On May 19, GCL Global announced a strategic investment from ADATA Technology to accelerate global entertainment and digital growth. This includes an additional $10 million investment in 4Divinity, significantly boosting the stock price. Source: Reuters

2. On May 19, GCL Global released relevant information through the EDGAR system, further confirming the investment details and enhancing market confidence. Source: Public Technologies

3. On May 20, Benzinga's stock ranking showed GCL maintaining a negative price trend in the short, medium, and long term; nevertheless, investors remain optimistic about its strategic investment. Source: Benzinga The market reacted positively to the strategic investment, focusing on capital flows.

Silexion pre-market up 111.26%. Based on recent key news:

1. On May 20, Silexion Therapeutics announced the exercise of warrants, generating total proceeds of $1 million. This news significantly boosted the stock price, and investors are optimistic about the company's future liquidity and development prospects. The biotechnology industry has been volatile recently